Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesdopetam - Integrative Research Laboratories

Drug Profile

Mesdopetam - Integrative Research Laboratories

Alternative Names: IRL-790

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integrative Research Laboratories
  • Developer Integrative Research Laboratories; Ipsen
  • Class Amines; Antiparkinsonians; Antipsychotics; Fluorobenzenes; Phenyl ethers; Small molecules; Sulfones
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Parkinson's disease
  • Phase I Drug-induced dyskinesia
  • Preclinical Psychotic disorders

Most Recent Events

  • 08 May 2024 IRLAB Therapeutics plans a phase III trial for Parkinson's disease
  • 22 Mar 2024 IRLAB Therapeutics receives written minutes from a recent end-of-phase II meeting for mesdopetam with the US FDA
  • 22 Feb 2024 Integrative Research Laboratories completes end of the phase II meeting with the FDA for mesdopetam
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top